Ocular myasthenia

Sui Hsien Wong, Michael Benatar

Research output: Contribution to journalArticle

Abstract

Ocular symptoms and signs are the most common clinical manifestation of myasthenia gravis (MG). Paradoxically, however, the ocular aspects of myasthenia are the least well studied and understood. We even lack good clinical outcome measures that might be used to quantify disease severity and impact on patient-reported outcome measures. In this chapter we discuss possible explanations for the predilection for ocular involvement in MG, the protean clinical manifestations of ocular disease, the challenges associated with reaching a confident diagnosis, and the risk of progression to generalized disease. With the exception of a small recent study of steroids in ocular myasthenia, clinical trials typically exclude ocular myasthenia patients. The result is uncertainty about important clinical questions such as the value of steroids and other immunosuppressive agents in mitigating the risk of progression to generalized disease and the uncertain role of thymectomy in the overall treatment of ocular myasthenia.

Original languageEnglish (US)
Pages (from-to)101-112
Number of pages12
JournalCurrent Clinical Neurology
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Myasthenia Gravis
Steroids
Thymectomy
Eye Diseases
Immunosuppressive Agents
Signs and Symptoms
Uncertainty
Outcome Assessment (Health Care)
Clinical Trials
Therapeutics
Patient Reported Outcome Measures

Keywords

  • Ocular myasthenia
  • Ophthalmoplegia
  • Ptosis Diplopia

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Ocular myasthenia. / Wong, Sui Hsien; Benatar, Michael.

In: Current Clinical Neurology, 01.01.2018, p. 101-112.

Research output: Contribution to journalArticle

Wong, Sui Hsien ; Benatar, Michael. / Ocular myasthenia. In: Current Clinical Neurology. 2018 ; pp. 101-112.
@article{9ca8bc5b4e4f4f4b922624fd7d3b4487,
title = "Ocular myasthenia",
abstract = "Ocular symptoms and signs are the most common clinical manifestation of myasthenia gravis (MG). Paradoxically, however, the ocular aspects of myasthenia are the least well studied and understood. We even lack good clinical outcome measures that might be used to quantify disease severity and impact on patient-reported outcome measures. In this chapter we discuss possible explanations for the predilection for ocular involvement in MG, the protean clinical manifestations of ocular disease, the challenges associated with reaching a confident diagnosis, and the risk of progression to generalized disease. With the exception of a small recent study of steroids in ocular myasthenia, clinical trials typically exclude ocular myasthenia patients. The result is uncertainty about important clinical questions such as the value of steroids and other immunosuppressive agents in mitigating the risk of progression to generalized disease and the uncertain role of thymectomy in the overall treatment of ocular myasthenia.",
keywords = "Ocular myasthenia, Ophthalmoplegia, Ptosis Diplopia",
author = "Wong, {Sui Hsien} and Michael Benatar",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-3-319-73585-6_7",
language = "English (US)",
pages = "101--112",
journal = "Current Clinical Neurology",
issn = "1559-0585",
publisher = "Springer Science + Business Media",

}

TY - JOUR

T1 - Ocular myasthenia

AU - Wong, Sui Hsien

AU - Benatar, Michael

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Ocular symptoms and signs are the most common clinical manifestation of myasthenia gravis (MG). Paradoxically, however, the ocular aspects of myasthenia are the least well studied and understood. We even lack good clinical outcome measures that might be used to quantify disease severity and impact on patient-reported outcome measures. In this chapter we discuss possible explanations for the predilection for ocular involvement in MG, the protean clinical manifestations of ocular disease, the challenges associated with reaching a confident diagnosis, and the risk of progression to generalized disease. With the exception of a small recent study of steroids in ocular myasthenia, clinical trials typically exclude ocular myasthenia patients. The result is uncertainty about important clinical questions such as the value of steroids and other immunosuppressive agents in mitigating the risk of progression to generalized disease and the uncertain role of thymectomy in the overall treatment of ocular myasthenia.

AB - Ocular symptoms and signs are the most common clinical manifestation of myasthenia gravis (MG). Paradoxically, however, the ocular aspects of myasthenia are the least well studied and understood. We even lack good clinical outcome measures that might be used to quantify disease severity and impact on patient-reported outcome measures. In this chapter we discuss possible explanations for the predilection for ocular involvement in MG, the protean clinical manifestations of ocular disease, the challenges associated with reaching a confident diagnosis, and the risk of progression to generalized disease. With the exception of a small recent study of steroids in ocular myasthenia, clinical trials typically exclude ocular myasthenia patients. The result is uncertainty about important clinical questions such as the value of steroids and other immunosuppressive agents in mitigating the risk of progression to generalized disease and the uncertain role of thymectomy in the overall treatment of ocular myasthenia.

KW - Ocular myasthenia

KW - Ophthalmoplegia

KW - Ptosis Diplopia

UR - http://www.scopus.com/inward/record.url?scp=85065811488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065811488&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-73585-6_7

DO - 10.1007/978-3-319-73585-6_7

M3 - Article

AN - SCOPUS:85065811488

SP - 101

EP - 112

JO - Current Clinical Neurology

JF - Current Clinical Neurology

SN - 1559-0585

ER -